Document is current

Article History

Received: 25 February 2025

Revised: 6 May 2025

Accepted: 14 May 2025

First Online: 23 May 2025

Declarations

:

: Wolfgang Uter receives research funds directed to the department by the International Fragrance Association (IFRA). Jim Bridges: is a member of the IDEA Supervisory Group; IDEA being sponsored by the International Fragrance Association. Margarida Gonçalo: Has participated in lectures and/or advisory boards and/or clinical trials for Abbvie, Almiral, Amgen, Astra-Zeneca, Biogen, Leo, Lilly, Novartis, Pfizer, Sanofi, Takeda. Stamatis Gregoriou: Lectures and/or advisory boards for Abbvie, Leo, Novartis, Pfizer, Sanofi, Lilly, UCB, Pierre Fabre, L’Oreal. Claudia C.V. Lang: is PI or investigator in several clinical trials, has received speaker fees, advisory fees and/or traveling reimbursement from the following companies: AbbVie, Amgen, ALK, Blueprint, Eli Lilly, Galderma, Incyte, Leo Pharma, Menarini AG, Novartis, Pfizer, Sanofi, Thermo Fisher. Suzana Ljubojevic Hadzavdic is a principal investigator of clinical studies for atopic dermatitis (Abbvie, Amgen) and for chronic spontaneous urticaria (Novartis). She wrote expert opinions and was lecturer for Lilly, Abbvie, Sanofi and Dr. Wolf. She is lecturer for Lilly, Novartis, Abbvie, Sanofi, Pliva, Bayer and Berlin-Chemie. Joseph Huggard works as a consultant for project IDEA sponsored by the International Fragrance Association (IFRA). Marléne Isaksson has worked as consultant for IDEA, sponsored by the International Fragrance Association (IFRA). Karl-Heinz Jöckel participates in the IDEA project sponsored by the International Fragrance Association (IFRA). Ian Kimber: is a member of the IDEA Supervisory Group; IDEA being sponsored by the International Fragrance Association. Elena Pezzolo has been a consultant, advisory board member, investigator, and/or speaker for Sanofi Genzyme, Pfizer, LEO Pharma, Eli Lilly, Almirall, Galderma, AbbVie, Novartis, Janssen, PellePharm, Boehringer Ingelheim, Bristol Myers Squibb. Thomas Rustemeyer has accepted honoraria for presentations from several pharmaceutical companies and is a member of the IDEA SG; IDEA being sponsored by the International Fragrance Association. Marie L.A. Schuttelaar has been a consultant, advisory board member, investigator, and/or speaker for Sanofi Genzyme, Regeneron Pharmaceuticals, Inc., Pfizer, LEO Pharma, Eli Lilly, Galderma, AbbVie, Novartis, Amgen. Cecilia Svedman participates in the IDEA project sponsored by the International Fragrance Association (IFRA). Matthias Vey is an employee of IFRA, International Fragrance Association. Magnus Bruze has lectured for Swedish Match and is a member of the Expert Panel for Fragrance Safety—. The other authors have no conflict of interest to declare.

: Institutional Review Board of Friedrich-Alexander University Erlangen/Nürnberg granted approval on 2024-04-24 (24-103-br) concerning data analysis. The study is conducted in accordance with the Declaration of Helsinki. Ethical approval was sought from every institutional review board associated with the clinics involved. Informed consent to the standard diagnostic procedure (patch testing), to its study-related extension by 7 patch test preparations, and to the storage and transmission for analysis of pseudonymized or anonymized data (depending on the data capture system used) is sought from and documented for every included patient.

: No identifiable patient characteristics will be published, i.e. not applicable.